Laurus Labs Ltd. · NSE:LAURUSLABS
Laurus Labs — Investor Presentation (September 2025)
24 slides from Laurus Labs's investor presentation, Sep 12, 2025
Slide 1: Exchange filing cover letter for investor presentation
September 12, 2025 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir /
Slide 2: Investor Presentation September 2025
Investor Presentation September 2025 © 2025 Laurus Labs Ltd.
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. W
Slide 4: Our Evolution - Transforming Laurus with Focus & Agility
Our Evolution - Transforming Laurus with Focus & Agility One Product API Company Formulation Integrated 2006-2011 2011-2016 2016-2021 Today • Small molecule APIs • Cell & Gene therapy • Formulation/DP Key • ARV4 API supplier with Global leadership in (Diabetic/CV, CNS • Microbial Fermentation • Flow
Slide 5: Our Strategy - Customer Centric focus anchored on High quality solutions
Our Strategy - Customer Centric focus anchored on High quality solutions VISION Leading player offering Integrated solutions Scale Integrated Quality & Innovation & Sustainability Talent Service Compliance Automation Strategic Large scale manufacturing sites Deliver long term Cultivate high performi
Slide 6: Integrated Large-Scale 'D & M' platform to support Global partners
Integrated Large-Scale ‘D & M’ platform to support Global partners R&D center Small Molecules R&D with Kilo lab, Hyderabad Unit 1 & 3, Vizag 3600 KL DS/DP Development 1 API/DS Manufacturing 1 2 3 4 5 6 7900 KL Reactors volumes New R&D, Hyderabad Unit 5, Vizag 161 KL DS Development 1 DS Manufacturing
Slide 7: R&D platform: Advancing Sustainable technology and Capability extension
R&D platform : Advancing Sustainable technology and Capability extension Significant Updates • Solidifying position on Flow/Bio-catalysis platform. Executed ton-level project >75 R&D projects* supported in FY25 utilizing proprietary designed flow reactors for high temp/pressure reactions • New R&D f
Slide 8: Leading Integrated CDMO and CMO platform to drive excellence
Leading Integrated CDMO and CMO platform to drive excellence CDMO Pre-Clinical Clinical supplies (Phase I, II and III) Commercial supplies Lifecycle management Small Molecules Specialized Modalities Animal Health and Crop Protection (Drug Substance & Drug Product) • Development & manufacturing servi
Slide 9: Our Business model continued to perform well through diversification
Our Business model continued to perform well through diversification Strong cumulative performance; Declining ARV concentration Broad portfolio of Customers Revenue by Geographical location CAGR % FY 20-25 FY 25 Revenue mix North America 14% 1 CDMO +32% +42% 28% 17% Europe 2 GENERICS +10% +2% 72% 69
Slide 10: CDMO market – Maintaining high market momentum
CDMO market – Maintaining high market momentum • Small molecules retains dominant modality • Tightening development timelines Market Trends • Demand for Integrated /Specialized • Supply chain de-risking by Big and Mid- capabilities pharma Small molecule CDMO market is structurally Laurus is well pos
Slide 11: CDMO: Recognized Industry Player, Demand for complex offerings driving Execution
CDMO: Recognized Industry Player, Demand for complex offerings driving Execution Revenue Growth Priorities • Strengthening Capabilities to meet complex demand and drive [₹ Cr] CAGR FY20-25 ▲ 29% next wave of accelerated growth 2,167 • On-going execution of pipeline opportunities • Focus on fully int
Slide 12: BIO – Focus on delivering Full service Precision Fermentation technology
BIO – Focus on delivering Full service Precision Fermentation technology Revenue Growth Priorities CAGR FY21-25 ▲ 29% • Expand Enzymatic / bio-catalysis application for small molecules [₹ Cr] • Increase product development throughput 160 160 • Commercial scale Capacity build up 125 100 Recent Highli
Slide 13: GENERICS – Integrated approach and Portfolio expansion to drive growth
GENERICS – Integrated approach and Portfolio expansion to drive growth Revenue Growth Priorities CAGR FY21-25 ▲ 10% • Capacity optimization, Cost efficiency [₹ Cr] • Expansion of CMO collaboration and Integrated supplies 4,286 3,919 3,959 4,020 3,749 Recent Highlights 2,621 +12% 2,039 2,438 2,448 2,
Slide 14: Other Updates
Other Updates KRKA joint venture1 • Commercial FDF capacity Groundbreaking ceremony of Finished formulation manufacturing facility in Hyderabad at 19 acres site • Invested ₹ 215 Cr in JV (incl. Laurus ₹ 105 Cr and KrKa ₹ 110 Cr) in FY25. Committed to invest over ₹ 500 Cr in initial phase From L to R
Slide 15: Cell and Gene therapy - Updates
Cell and Gene therapy - Updates Cell therapy Gene therapy • NexCAR19 Continued demand > 350 infusions as on June’25. • Break ground on new dedicated Gene/Anti-body Drug Successful infusion for CD-19 Pediatric Trial (Phase II) Conjugates R&D and manufacturing facility in Genome valley Hyderabad (>650
Slide 16: Promoting ESG agenda and Enhancing competitive advantage
Promoting ESG agenda and Enhancing competitive advantage S&P Global ESG Score 73 Inclusion in S&P Global Sustainability Committed to Near- Improved S&P ESG Consecutive “BBB” Yearbook 2025 & term GHG targets Score Vs. 59/100 LY ratings in FY22-25 Only company to be Named “Industry Mover” from Pharma
Slide 17: Ongoing strategic investment to drive growth
Ongoing strategic investment to drive growth >85% Growth CAPEX across API / CDMO portfolio supported by Drug product approach Phase-wise Split of Investments • 50% of CAPEX added in FY22-25 8% • 90% invested in Large Scale manufacturing 23% assets 33% ~ ₹ 3,400 Cr 2 Total CAPEX • Groundbreaking of G
Slide 18: Continued recovery in asset turnover levels and resilient margins
Continued recovery in asset turnover levels and resilient margins • Continued recovery in asset turns at expanded gross (~6 Quarters) 1.5x margins since mid-FY25 following significant CDMO - Long lead times for - High value CDMO project deliveries 54% Complex CDMO project deliveries and projects ram
Slide 19: Healthy OCF and Continued Capex to support future growth
Healthy OCF and Continued Capex to support future growth Operating Cash flows and CAPEX investments Leverage profile [₹ Crores] 350% 40% 994 990 950 2.9x 911 300% 34% 35% 2.3x 30% 733 250% 689 700 2.0x 666 659 25% 602 200% 24% 1.8x Asset under-utilization 21% and upfront spends in 20% growth project
Slide 20: Financial Highlights FY 2020-25
Financial Highlights FY 2020-25 Revenues EBITDA & Gross Profit Margins [₹ Cr] CAGR: +14% 4000 [₹ Cr] CAGR: +14% 70.0% 3500 59.4% 60.0% GPM 3000 55.2% 55.5% 54.1% 55.4% 2500 50.1% 51.7% 50.0% 32.7% 29.1% 40.0% 26.4% 2000 6,041 24.8% OPM 5,554 20.1% 20.1% 30.0% 5,041 1500 4,814 4,936 15.8% 20.0% 1000
Slide 21: Appendix
Appendix Pinus Labs
Slide 22: 1Q FY26: Executive Summary
1Q FY26: Executive Summary • Strong performance continued in Q1; ₹ 1,570 Cr Revenues and 31% revenues growth • Attractive market opportunities favoring robust CDMO momentum, expanding collaboration in complex API and growth in Generics • ₹ 389 Cr EBITDA resulted in a margin of 24.8%, improving by 10
Slide 23: 1Q FY26: Financial performance
1Q FY26: Financial performance 1Q FY26 Financial Summary Comments [₹ Crore] 4Q FY25 1Q FY26 1Q FY25 Y-o-Y Q-o-Q • Revenues : ₹ 1,570 Cr, increased 31% primarily driven by robust CDMO performance while growth in generic FDF partly offset by lower API business Revenues 1,720 1,570 1,195 31% -9% • Gros
Slide 24: Additional Information
Additional Information Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral